Perfluorotetradecanoic acid

Perfluorotetradecanoic acid (PFTeDA) is a PPARγ inhibitor. Perfluorotetradecanoic acid binds to human PPARγ ligand binding domain with IC50 of 22.8 μM, Kd of 157.8 μM. Perfluorotetradecanoic acid inhibits the function of Leydig cells by inducing oxidative stress and apoptosis. Perfluorotetradecanoic acid stimulates corticosterone biosynthesis but inhibits aldosterone production[1][2][3].

Product Specifications

CAS Number

[376-06-7]

Product Name Alternative

PFTeDA

UNSPSC

12352211

Hazard Statement

H302+H332, H351, H360, H362, H372

Target

Apoptosis; PPAR

Related Pathways

Apoptosis; Cell Cycle/DNA Damage; Metabolic Enzyme/Protease; Vitamin D Related/Nuclear Receptor

Field of Research

Endocrinology

Purity

98.0

Smiles

O=C(C(F)(C(F)(C(F)(C(F)(C(F)(C(F)(C(F)(C(F)(C(F)(C(F)(C(F)(C(F)(C(F)(F)F)F)F)F)F)F)F)F)F)F)F)F)F)O

Molecular Formula

C14HF27O2

Molecular Weight

714.11

Precautions

H302+H332, H351, H360, H362, H372

References & Citations

[1]Zhang L, et al. Structure-dependent binding and activation of perfluorinated compounds on human peroxisome proliferator-activated receptor γ. Toxicol Appl Pharmacol. 2014 Sep 15;279 (3) :275-283.|[2]Tang Y, et al. Leydig cell function in adult male rats is disrupted by perfluorotetradecanoic acid through increasing oxidative stress and apoptosis. Environ Toxicol. 2022 Jul;37 (7) :1790-1802.|[3]Ying Y, et al. Perfluorotetradecanoic acid exposure to adult male rats stimulates corticosterone biosynthesis but inhibits aldosterone production. Environ Toxicol. 2024 May;39 (5) :2610-2622.